AbbVie Inc. (ABBV) Dividends CAGR:5.81%(TTM)
The dividends cagr for AbbVie Inc. (ABBV) is +5.81% over the latest trailing 12-month period. Dividends CAGR uses precomputed dividend-per-share history.
The dividends CAGR for AbbVie Inc. (ABBV) stock is 5.81% over the past 12 months. The 3 year CAGR is 5.16% and the 5 year CAGR is 6.81%. Dividends CAGR shows the annualized change in AbbVie Inc.'s dividend payments per share over the selected period.
ABBV Dividends CAGR Chart
AbbVie Inc. (ABBV)
ABBV Dividends CAGR History
| Year | Start Dividend/Share | End Dividend/Share | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $6.20 | $6.56 | +$0.36 | +5.81% | +5.81% |
| 2024 | $5.92 | $6.20 | +$0.28 | +4.73% | +4.73% |
| 2023 | $5.64 | $5.92 | +$0.28 | +4.96% | +4.96% |
| 2022 | $5.20 | $5.64 | +$0.44 | +8.46% | +8.46% |
| 2021 | $4.72 | $5.20 | +$0.48 | +10.17% | +10.17% |
| 2020 | $4.28 | $4.72 | +$0.44 | +10.28% | +10.28% |
| 2019 | $3.59 | $4.28 | +$0.69 | +19.22% | +19.22% |
| 2018 | $2.56 | $3.59 | +$1.03 | +40.23% | +40.23% |
| 2017 | $2.28 | $2.56 | +$0.28 | +12.28% | +12.28% |
| 2016 | $2.02 | $2.28 | +$0.26 | +12.87% | +12.87% |
| 2015 | $1.66 | $2.02 | +$0.36 | +21.69% | +21.69% |
| 2014 | $1.60 | $1.66 | +$0.06 | +3.75% | +3.75% |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael